Dendreon’s Provenge Cancer Vaccine Shows “Substantial Efficacy” – Cmte.
Executive Summary
Although not convinced that existing data fully prove the efficacy of Dendreon's Provenge, a majority of FDA's Cellular, Tissue and Gene Therapies Advisory Committee agreed during a March 29 meeting that there is "substantial evidence" the biologic is effective and should be approved
You may also be interested in...
Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
Survival Endpoints, Rigorous Phase IIs May Boost Cancer Vaccines’ Success
SAN FRANCISCO - Stronger endpoints for survival and more rigorously designed Phase II trials are what will push the development of therapeutic cancer vaccines closer to the finish line, an industry panel said at a recent meeting at the Biotechnology Industry Organization Investor Forum